恶性血液病合并血流感染患者病原菌分布及其预后影响因素
作者:
作者单位:

遵义医科大学附属医院血液内科, 贵州  遵义 563000

通讯作者:

袁钟  E-mail: Yuanzhong1963@126.com

中图分类号:

+2]]>

基金项目:

遵义医科大学硕士启动基金[院字2018(27号)]


Distribution of pathogenic bacteria and factors affecting prognosis of patients with malignant hematological diseases complicated with blood stream infection
Author:
Affiliation:

Department of Hematology, Affiliated Hospital of Zunyi Medical University, Zunyi 563000, China

  • 摘要
  • |
  • 访问统计
  • |
  • 参考文献 [31]
  • |
  • 相似文献
  • |
  • 文章评论
    摘要:

    目的 分析恶性血液病合并血流感染患者的病原学特征及其预后影响因素。 方法 选取2016年1月-2022年5月遵义医科大学附属医院血液内科的恶性血液病合并血流感染的住院患者为研究对象。根据患者发生血流感染30 d内的治疗结局分为生存组和死亡组。分析患者的病原学特征及预后情况, 并采用单因素及logistic回归分析影响恶性血液病合并血流感染预后的危险因素。 结果 共纳入185例患者, 基础疾病以急性白血病为主(125例, 67.6%)。共分离197株病原菌, 革兰阴性菌109株(55.3%), 其中大肠埃希菌55株(27.9%); 革兰阳性菌86株(43.7%), 其中人葡萄球菌24株(12.2%); 真菌2株(1.0%)。大肠埃希菌中产超广谱β-内酰胺酶(EBSLs)菌株28株(50.9%); 肺炎克雷伯菌中产EBSLs菌株2株(10.0%); 耐甲氧西林的人葡萄球菌、表皮葡萄球菌、金黄色葡萄球菌的检出率分别为70.8%、71.4%、36.4%。单因素分析表明, 年龄≥70岁、粒细胞缺乏持续时间≥7 d、未合理使用抗菌药物、合并心功能不全、合并急性肾功能不全、感染性休克、肺部感染患者的30天病死率较高, 差异均有统计学意义(均P < 0.05)。多因素logistic回归分析表明, 粒细胞缺乏持续时间≥7 d[OR=3.306, 95%CI(1.224~8.927)]、合并心功能不全[OR=6.291, 95%CI(1.930~20.508)]、合并急性肾功能不全[OR=8.419, 95%CI(2.198~32.241)]、感染性休克[OR=22.150, 95%CI(3.639~134.806)]均为恶性血液病合并血流感染患者30天内死亡的独立危险因素(均P < 0.05)。 结论 恶性血液病合并血流感染最常见的病原菌中, 革兰阴性菌以大肠埃希菌为主, 革兰阳性菌以人葡萄球菌为主。影响恶性血液病合并血流感染患者预后的危险因素较多, 缩短粒细胞缺乏持续时间, 改善心功能不全、肾功能不全, 积极控制感染性休克是减少恶性血液病合并血流感染患者30天内死亡的有效措施。

    Abstract:

    Objective To analyze the pathogenic characteristics and affecting factors for prognosis of patients with malignant hematological diseases complicated with blood stream infection (BSI). Methods Hospitalized patients with malignant hematological diseases complicated with BSI in the Department of Hematology in Affiliated Hospital of Zunyi Medical University between January 2016 and May 2022 were selected as the study subjects.Patients were divided into survival group and death group according to the treatment outcome within 30 days after BSI.Pathogenic characteristics and prognosis of patients were analyzed, risk factors for the prognosis of malignant hematological diseases complicated with BSI were analyzed by univariate and logistic regression. Results A total of 185 patients were included in study, the main underlying disease was acute leukemia (n=125, 67.6%).197 strains of pathogenic bacteria were isolated, 109 strains (55.3%) were Gram-negative bacteria, 55(27.9%) of which was Escherichia coli; 86 strains (43.7%) were Gram-positive bacteria, 24(12.2%) of which were Staphylococcus hominis; 2 strains were fungi (1.0%).28 strains (50.9%) of Escherichia coli and 2 strains (10.0%) of Klebsiella pneumoniae produced extended-spectrum β-lactamases.Isolation rates of methicillin-resistant coagulase negative staphylococcus, methicillin-resistant Staphylococcus epidermidis and methicillin-resistant Staphylococcus aureus were 70.8%, 71.4% and 36.4% respectively; univariate analysis showed that 30-day mortality was higher in patients with age ≥ 70 years, duration of agranulocytosis ≥ 7 days, irrational use of antimicrobial agents, combined with cardiac insufficiency, combined with acute renal insufficiency, septic shock and pulmonary infection, diffe-rences were all significant (all P < 0.05).Multivariate logistic regression analysis showed that duration of agranulocytosis ≥ 7 days (OR=3.306, 95%CI[1.224-8.927]), combined with cardiac insufficiency (OR=6.291, 95%CI[1.930-20.508]), combined with acute renal insufficiency (OR=8.419, 95%CI[2.198-32.241]), and septic shock (OR=22.150, 95%CI[3.639-134.806]) were all independent risk factors for 30-day mortality in patients with malignant hematological diseases complicated with BSI (all P < 0.05). Conclusion Among the most common pathogenic bacteria of malignant hematological diseases complicated with BSI, Escherichia coli is the main Gram-negative bacteria, and Staphylococcus hominis is the main Gram-positive bacteria.There are multiple risk factors affecting the prognosis of patients with malignant hematological diseases complicated with BSI.Shortening the duration of agranulocytosis, improving cardiac and renal function, and actively controlling septic shock are effective measures to reduce 30-day mortality in patients with malignant hematological diseases complicated with BSI.

    参考文献
    [1] Gustinetti G, Mikulska M. Bloodstream infections in neutropenic cancer patients: a practical update[J]. Virulence, 2016, 7(3): 280-297.
    [2] Mitrovic M, Suvajdzic N, Elezovic I, et al. Thrombotic events in acute promyelocytic leukemia[J]. Thromb Res, 2015, 135(4): 588-593.
    [3] Del Principe MI, Buccisano F, Soddu S, et al. Involvement of central nervous system in adult patients with acute myeloid leukemia: incidence and impact on outcome[J]. Semin Hematol, 2018, 55(4): 209-214.
    [4] Cherruault M, Le Goff M, Tamburini J, et al. Urgent chemotherapy in sepsis-like shock related to hematologic malignancies[J]. Crit Care Med, 2018, 46(5): e465-e468.
    [5] 袁海龙, 古力巴旦木·艾则孜, 曹海洲, 等. 血液肿瘤患者感染病原菌分布与耐药性研究[J]. 中华医院感染学杂志, 2016, 26(4): 812-814.
    [6] 周梦兰, 杨启文, 于淑颖, 等. 血流感染流行病学研究进展[J]. 中国感染与化疗杂志, 2019, 19(2): 212-217.
    [7] Rhee C, Dantes R, Epstein L, et al. Incidence and trends of sepsis in US hospitals using clinical vs claims data, 2009-2014[J]. JAMA, 2017, 318(13): 1241-1249.
    [8] Trecarichi EM, Giuliano G, Cattaneo C, et al. Bloodstream infections caused by Escherichia coli in onco-haematological patients: risk factors and mortality in an Italian prospective survey[J]. PLoS One, 2019, 14(10): e0224465.
    [9] Trecarichi EM, Pagano L, Candoni A, et al. Current epidemio- logy and antimicrobial resistance data for bacterial bloodstream infections in patients with hematologic malignancies: an Italian multicentre prospective survey[J]. Clin Microbiol Infect, 2015, 21(4): 337-343.
    [10] 左金曼. 恶性血液病合并血流感染临床分析[D]. 合肥: 安徽医科大学, 2017. Zuo JM. A clinical analysis of malignant hematology with bloodstream infection[D]. Hefei: Anhui Medical University, 2017.
    [11] 陈少桢. 血液恶性肿瘤化疗患者并发血流感染的流行病学及危险因素分析[D]. 福州: 福建医科大学, 2019. Chen SZ. The epidemiology and risk factors for the emergence and mortality of bloodstream infections in patients with hematological malignancy receiving chemotherapy[D]. Fuzhou: Fujian Medical University, 2019.
    [12] 王辉, 张悦娴, 谢秀丽, 等. 血培养凝固酶阴性葡萄球菌阳性的临床意义[J]. 中国抗感染化疗杂志, 2001, 1(2): 79-82.
    [13] 沈悌, 赵永强, 周道斌, 等. 血液病诊断及疗效标准[M]. 4版. 北京: 科学出版社, 2018.
    [14] 中华人民共和国卫生部. 医院感染诊断标准(试行)[J]. 中华医学杂志, 2001, 81(5): 314-320.
    [15] 杨祖耀, 詹思延, 王波, 等. 中国血流感染住院病死率的系统评价和meta分析[J]. 北京大学学报(医学版), 2010, 42(3): 304-307.
    [16] 王舒莉, 崔渤莉, 孟月生, 等. 恶性血液病患者血流感染病原菌特点及危险因素分析[J]. 中华医院感染学杂志, 2014, 24(13): 3182-3184.
    [17] 国家卫生计生委合理用药专家委员会, 全国细菌耐药监测网. 2018年全国细菌耐药监测报告[J]. 中国合理用药探索, 2020, 17(1): 1-10.
    [18] 孟雪斐, 张鸿娟, 马志刚, 等. 2018—2020年多中心血流感染分离菌分布及耐药性分析[J]. 中国抗生素杂志, 2021, 46(11): 985-993.
    [19] Peirano G, Pitout JDD. Extended-spectrum β-lactamase-producing Enterobacteriaceae: update on molecular epidemiology and treatment options[J]. Drugs, 2019, 79(14): 1529-1541.
    [20] Diriba K, Awulachew E, Gemede A, et al. The magnitude of extended-spectrum beta-lactamase-producing Enterobacteriaceae from clinical samples in Ethiopia: a systematic review and Meta-analysis[J]. Access Microbiol, 2021, 3(3): 000195.
    [21] Xiao SZ, Tang CY, Zeng Q, et al. Antimicrobial resistance and molecular epidemiology of Escherichia coli from bloodstream infection in Shanghai, China, 2016-2019[J]. Front Med (Lausanne), 2021, 8: 803837.
    [22] MacKinnon MC, McEwen SA, Pearl DL, et al. Increasing incidence and antimicrobial resistance in Escherichia coli bloodstream infections: a multinational population-based cohort study[J]. Antimicrob Resist Infect Control, 2021, 10(1): 131.
    [23] K?os M, Pomorska-Weso?owska M, Romaniszyn D, et al. Antimicrobial resistance in Enterobacterales bacilli isolated from bloodstream infection in surgical patients of Polish hospitals[J]. Int J Microbiol, 2021, 2021: 6687148.
    [24] Baker TM, Satlin MJ. The growing threat of multidrug-resis-tant Gram-negative infections in patients with hematologic malignancies[J]. Leuk Lymphoma, 2016, 57(10): 2245-2258.
    [25] 中华医学会血液学分会, 中国医师协会血液科医师分会. 中国中性粒细胞缺乏伴发热患者抗菌药物临床应用指南(2020年版)[J]. 中华血液学杂志, 2020, 41(12): 969-978.
    [26] Yang CC, Sy CL, Huang YC, et al. Risk factors of treatment failure and 30-day mortality in patients with bacteremia due to MRSA with reduced vancomycin susceptibility[J]. Sci Rep, 2018, 8(1): 7868.
    [27] 李丽, 周敏, 乔丹, 等. 恶性血液病患者继发感染病原菌分布及其耐药性分析[J]. 检验医学, 2020, 35(3): 189-194.
    [28] 张国扬, 杨鹏凤, 王秀菊, 等. 血液病住院患者血流感染死亡危险因素分析[J]. 中山大学学报(医学科学版), 2017, 38(4): 622-627.
    [29] Cimolai MC, Alvarez S, Bode C, et al. Mitochondrial mechanisms in septic cardiomyopathy[J]. Int J Mol Sci, 2015, 16(8): 17763-17778.
    [30] Dellepiane S, Marengo M, Cantaluppi V. Detrimental cross-talk between sepsis and acute kidney injury: new pathogenic mechanisms, early biomarkers and targeted therapies[J]. Crit Care, 2016, 20: 61.
    [31] Sood MM, Shafer LA, Ho J, et al. Early reversible acute kidney injury is associated with improved survival in septic shock[J]. J Crit Care, 2014, 29(5): 711-717.
    相似文献
引用本文

高陆,刘维佳,袁钟.恶性血液病合并血流感染患者病原菌分布及其预后影响因素[J]. 中国感染控制杂志,2022,(9):891-898. DOI:10.12138/j. issn.1671-9638.20222708.
Lu GAO, Wei-jia LIU, Zhong YUAN. Distribution of pathogenic bacteria and factors affecting prognosis of patients with malignant hematological diseases complicated with blood stream infection[J]. Chin J Infect Control, 2022,(9):891-898. DOI:10.12138/j. issn.1671-9638.20222708.

复制
分享
文章指标
  • 摘要阅读次数:179
  • 下载次数: 372
  • HTML阅读次数: 435
  • 引用次数: 0
历史
  • 收稿日期:2022-03-31
  • 在线发布日期: 2024-04-28